Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.
A big investment bank still thinks Dyne Therapeutics is worth owning, but they lowered how high they think the price could go. This is like saying "I still like this company, but I'm being more careful about how much I think it's worth."
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.